Navigation Links
New Prostate Cancer Drug May Hold Promise

Researchers apply for large-scale testing after 'very promising' early results,,

TUESDAY, April 7 (HealthDay News) -- A new drug with a radically different way of attacking prostate cancer has done well in an initial trial and is ready for larger-scale testing, researchers report.

One standard treatment for the malignancy is to inhibit the activity of androgens, male hormones such as testosterone that help drive tumor growth. Existing anti-androgens try to "shut down the factory" that produces the hormones, but the new drug blocks the receptors for those androgens on the tumor cells, said Dr. Howard I. Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City and co-author of a report to be published online by the journal Science.

"There is a lot of interest in the drug, because the preliminary results are very promising," Scher said.

The report in the journal describes the results of the treatment of 30 men with advanced prostate cancer that was not responding to conventional anti-androgen therapy. After treatment with the drug, there were "sustained declines" in blood levels of prostate specific antigen, a biomarker of tumor growth, in 13 of the 30, or 43 percent, which the report called a "promising" result.

The researchers now have data on 114 men given the drug, Scher said. "It showed not only declines in PSA but also regression of the tumor on scans and also that circulating tumor cell counts, another measure of treatment, converted from unfavorable to favorable in a considerable percentage of patients," he said.

Based on those results, Scher said, an application for a large-scale trial has been submitted to the U.S. Food and Drug Administration by Medivation Inc., a California-based biopharmaceutical company that has licensed the drug, now called MDV3100. The hope is that the trial will lead to FDA approval of the drug for clinical use.

The trial would be international in scope, he said, but the length and size have not been determined.

MDV3100 came out of research done at the University of California, Los Angeles, by Dr. Charles L. Sawyers, a cancer biologist who now is chairman of the human oncology and pathogenesis program at Sloan-Kettering.

"My laboratory was studying why men develop resistance to current anti-androgen drugs," Sawyers said. "We found that resistant tumors have higher levels of androgen receptors. What we showed was that cells, by making more of these receptors, can escape those drugs. Based on that, we developed a cell line that made higher levels of receptors and used that as a screen for compounds that could block the receptors."

Sawyers did the research in collaboration with a group led by Michael Jung, a chemist at UCLA. "We had some ideas about what chemical structures we might need to get such a result," Sawyers said. "His group synthesized a set of compounds, my group screened them, and over the months, we learned what to do. There were a number of chemicals known to bind to a receptor with different affinities, and we made derivatives of them."

That work produced more than one effective receptor blocker. MDV3100 was selected as the most promising.

Though the immediate goal is to get FDA approval for use of the drug in men whose prostate cancers do not respond to existing anti-androgen therapy, the ultimate hope is that it could be used for first-line therapy, Scher and Sawyers said.

"That is a typical scenario," Sawyers said. "First you test it in late-stage patients. If it is effective there, you would want to move it to front-line therapy."

About half of all prostate cancers have the overgrowth of androgen receptors that MDV3100 is designed to attack, Scher noted.

Side effects do not appear to be a problem, Sawyers said. "At high doses, fatigue has been a problem in some men -- higher doses than are needed to get benefit," he said.

More information

The U.S. National Cancer Institute has more on prostate cancer.

SOURCES: Howard I. Scher, M.D., chief, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, New York City; Charles L. Sawyers, M.D., chairman, human oncology and pathogenesis program, Memorial Sloan-Kettering Cancer Center, New York City; April 9, 2009, Science, online

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
Related Image:
New Prostate Cancer Drug May Hold Promise
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android ... The new app features a more intuitive SleepScore™ that rates sleep quality on a ... The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving (MADD) ... below 10,000 for the first time since 2011. In 2014, there were 9,967 fatalities ... released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in ...
(Date:11/25/2015)... ... 2015 , ... Privately owned Contract Development and Manufacturing Organization ... current state of the art research, development and manufacturing facility outside of Fort ... capacity as well as to support its clients’ growing research and development and ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Today AVACEN Medical announced the issue of ... Thermal Energy Including Blood Viscosity Adjustment ". This patent shields the company,s AVACEN 100 dry heat ... Treatment Method. Photo - ... ... ...
Breaking Medicine Technology: